Quantcast
The MFWire
Manage Email Alerts | Sponsorships | About MFWire | Who We Are

Subscribe to MFWire.com's News Alerts [click]

Rating:Closed Enders Can Swallow Poison Pills Not Rated 5.0 Email Routing List Email & Route  Print Print
Monday, October 25, 2004

Closed Enders Can Swallow Poison Pills

by: Sean Hanna, Editor in Chief

Closed-end funds may have another defense against unwanted investors hoping to take control of the fund. A recent court ruling in a case involving a Neuberger Berman fund upheld a poison pill provision protecting the fund manager.

The ruling was made Friday by U.S. District Court for the District of Maryland Judge Andre Davis in a case brought by Stewart Horejsi, an investor who had attempted to take control of the funds through an unsolicited offer, against the Neuberger Berman Real Estate Income Fund Inc., reports the Wall Street Journal.

Horejsi had contended that the fund's shareholder rights agreement violated several provisions of the Investment Company Act of 1940. The rights agreement would have diluted Horejsi's shares through a self-tender offer entitling shareholders to buy three shares of common stock at par value. The provision was triggered 10 days after a public announcement that one or a group of stockholders have acquired 11 percent or more of the shares outstanding.

The case involves the first test of a poison pill provision used by a closed-end fund.

Judge Davis wrote that the poison pill provision adhered to the 1940 act because, when triggered, "it allows for all shareholders, except the Acquiring Person, to exercise their rights" and that the "poison pill does not change the fact that all shares are granted equal voting rights."  

Stay ahead of the news ... Sign up for our email alerts now
CLICK HERE

5.0
 Do You Recommend This Story?



GO TO: MFWire
Return to Top
 News Archives
2024: Q2Q1
2023: Q4Q3Q2Q1
2022: Q4Q3Q2Q1
2021: Q4Q3Q2Q1
2020: Q4Q3Q2Q1
2019: Q4Q3Q2Q1
2018: Q4Q3Q2Q1
2017: Q4Q3Q2Q1
2016: Q4Q3Q2Q1
2015: Q4Q3Q2Q1
2014: Q4Q3Q2Q1
2013: Q4Q3Q2Q1
2012: Q4Q3Q2Q1
2011: Q4Q3Q2Q1
2010: Q4Q3Q2Q1
2009: Q4Q3Q2Q1
2008: Q4Q3Q2Q1
2007: Q4Q3Q2Q1
2006: Q4Q3Q2Q1
2005: Q4Q3Q2Q1
2004: Q4Q3Q2Q1
2003: Q4Q3Q2Q1
2002: Q4Q3Q2Q1
 Subscribe via RSS:
Raw XML
Add to My Yahoo!
follow us in feedly


  1. IMEA CMO Roundtable, May 14
  2. Envestnet Elevate 2024, May 14-15
  3. The Expect Miracles Foundation 5th Annual Distance Challenge, May 14-21
  4. ALFI Golf Tournament In New York, May 14
  5. MFDF webinar - The Improvisational Leader Callback Session, May 14
  6. ICI & ASECA: Celebrating 100 Years of the Mutual Fund, May 14
  7. WE U.S. - 10th Annual Event at InsideETFs, May 14
  8. WE Boston - Women's Initiative Joint Spring Networking Reception, May 15
  9. SEC IM 2024 Conference on Emerging Trends in Asset Management, May 16
  10. MFDF In Focus: Making Sense of ESG - A Morningstar Guide, May 16
  11. ALFI Roadshow to the USA, May 16
  12. 2024 ICI Leadership Summit, May 21-23
  13. MFDF webinar - Mutual Fund Director Compensation: the MPI Annual Survey (2024), May 21
  14. Schwab Institutional Investor Day, May 22
  15. MFDF Conference of Fund Leaders Forum, June 5
  16. MFDF in-person outreach: Continuing Regulatory Impacts on Fund Boards, June 11
  17. 2024 Nicsa Fearless Leadership Symposium, June 12
  18. 2024 MMI Leadership Pathway Seminar, Jun 12-14
  19. MFDF webinar - Digital Assets in the Fund Space (Part 1 of 2), June 12
  20. MFDF webinar - Lessons Learned from the Regional Bank Volatility and the Impact on Registered Funds, June 18
  21. MFDF Director Discussion Series - Open Forum (Philadelphia), June 20
  22. New York YPEM Cornhole Classic, June 25
  23. Morningstar Investment Conference Conference 2024, Jun 26-27
  24. MFDF webinar - Mid-Year Tax Update for Registered Investment Companies, July 16
  25. MFDF Director Discussion Series - Open Forum via Zoom, July 17
  26. MFDF Director Discussion Series - Open Forum (New York), July 23




©All rights reserved to InvestmentWires, Inc. 1997-2024
14 Wall Street | 20th Floor | New York, NY 10005 | P: 212-331-8968 | F: 212-331-8998
Privacy Policy :: Terms of Use